Trevi Therapeutics, Inc.(TRVI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TRVI Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Trevi Therapeutics, Inc. (TRVI), a Healthcare sector company. TRVI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Trevi Therapeutics, Inc. reports net income of $-17.8M, free cash flow of $-17.6M. Top institutional holders of TRVI by reported 13-F value include NEA Management Company, FMR, BlackRock, based on the most recent SEC filings. TRVI trades on the Nasdaq exchange and files with the SEC under CIK 1563880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Trevi Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-17.8M
Free Cash Flow
Q2 2026
$-17.6M
ROIC
Q2 2026
-25.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+10.8% YoYOperating Income
+4.3% YoYEPS (Diluted)
+31.9% YoYTotal Assets
+74.4% YoYOp. Cash Flow
-10.0% YoYFree Cash Flow
-10.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-42.8M +10.8% | $-47.9M -64.8% | $-29.1M +0.3% | $-29.2M +14.1% | $-33.9M -3.6% | $-32.8M |
| Operating Income | $-49.3M +4.3% | $-51.5M -51.9% | $-33.9M -13.4% | $-29.9M +7.9% | $-32.5M +0.0% | $-32.5M |
| EPS (Diluted) | $-0.32 +31.9% | $-0.47 -62.1% | $-0.29 +35.6% | $-0.45 +69.8% | $-1.49 | — |
| Total Assets | $193.4M +74.4% | $110.9M +24.0% | $89.4M -27.3% | $123.0M +219.7% | $38.5M -18.4% | $47.1M |
| Operating Cash Flow | $-42.1M -10.0% | $-38.3M -20.6% | $-31.7M -12.5% | $-28.2M +2.7% | $-28.9M +0.2% | $-29.0M |
| Free Cash Flow | $-42.1M -10.0% | $-38.3M -20.2% | $-31.8M -12.4% | $-28.3M | — | $-29.0M |
Get alerted when TRVI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Trevi Therapeutics, Inc. including:
Top Institutional Holders of TRVI
NEA Management Company, LLC
$246.6M13,222,228 shFMR LLC
$234.3M12,562,839 shBlackRock, Inc.
$208.0M11,155,026 shFrazier Life Sciences Management, L.P.
$185.4M9,939,447 shWELLINGTON MANAGEMENT GROUP LLP
$106.0M5,684,592 shVANGUARD CAPITAL MANAGEMENT LLC
$103.1M5,530,675 shVivo Capital, LLC
$95.0M5,094,668 shWoodline Partners LP
$76.1M4,081,333 shVestal Point Capital, LP
$57.8M3,100,000 shMPM BioImpact LLC
$57.3M3,073,577 sh
| Fund | Value | Shares |
|---|---|---|
| NEA Management Company, LLC | $246.6M | 13,222,228 |
| FMR LLC | $234.3M | 12,562,839 |
| BlackRock, Inc. | $208.0M | 11,155,026 |
| Frazier Life Sciences Management, L.P. | $185.4M | 9,939,447 |
| WELLINGTON MANAGEMENT GROUP LLP | $106.0M | 5,684,592 |
| VANGUARD CAPITAL MANAGEMENT LLC | $103.1M | 5,530,675 |
| Vivo Capital, LLC | $95.0M | 5,094,668 |
| Woodline Partners LP | $76.1M | 4,081,333 |
| Vestal Point Capital, LP | $57.8M | 3,100,000 |
| MPM BioImpact LLC | $57.3M | 3,073,577 |
More Healthcare Companies
View all Healthcare →Put TRVI on your watchlist
Track score changes the day Trevi Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TRVI a good stock to buy?
13F Pro's AI-powered analysis of Trevi Therapeutics, Inc. (TRVI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRVI are available on the TRVI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TRVI is classified as a mid company.
Which hedge funds own TRVI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRVI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Trevi Therapeutics, Inc.'s investment landscape.